These data are consistent with publications showing that co-mutation of KRAS and TP53 is characteristic of non-small-cell lung cancer [26], and it can be considered a prognostic marker for the effectiveness of immune checkpoint blockade. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.